Concepts (227)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Compartment Syndromes | 4 | 2022 | 39 | 2.320 |
Why?
|
Muscle, Skeletal | 8 | 2022 | 519 | 2.310 |
Why?
|
Aging | 4 | 2017 | 946 | 1.040 |
Why?
|
Regeneration | 4 | 2016 | 170 | 1.040 |
Why?
|
Rats, Inbred Lew | 7 | 2022 | 118 | 0.900 |
Why?
|
Cell Differentiation | 7 | 2022 | 469 | 0.870 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2022 | 15 | 0.820 |
Why?
|
Radiobiology | 1 | 2020 | 5 | 0.710 |
Why?
|
Acetylcysteine | 1 | 2020 | 11 | 0.700 |
Why?
|
Animals | 21 | 2022 | 7542 | 0.670 |
Why?
|
Disease Models, Animal | 5 | 2020 | 1022 | 0.650 |
Why?
|
Receptors, Transforming Growth Factor beta | 2 | 2008 | 9 | 0.620 |
Why?
|
Stem Cells | 3 | 2020 | 313 | 0.620 |
Why?
|
Proteoglycans | 2 | 2008 | 32 | 0.610 |
Why?
|
Muscle Fibers, Skeletal | 4 | 2017 | 109 | 0.610 |
Why?
|
Growth Differentiation Factors | 1 | 2016 | 2 | 0.570 |
Why?
|
Tissue Engineering | 5 | 2014 | 656 | 0.560 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2016 | 23 | 0.560 |
Why?
|
Molecular Chaperones | 3 | 2005 | 13 | 0.540 |
Why?
|
Recovery of Function | 2 | 2014 | 199 | 0.530 |
Why?
|
Glycoproteins | 3 | 2005 | 45 | 0.530 |
Why?
|
Neovascularization, Physiologic | 2 | 2020 | 110 | 0.440 |
Why?
|
Rats | 5 | 2022 | 1596 | 0.440 |
Why?
|
Transcription Factors | 2 | 2005 | 181 | 0.430 |
Why?
|
Myoblasts | 3 | 2017 | 38 | 0.420 |
Why?
|
Muscles | 1 | 2012 | 62 | 0.410 |
Why?
|
Mice | 8 | 2022 | 2484 | 0.380 |
Why?
|
Genes, Tumor Suppressor | 2 | 2007 | 34 | 0.360 |
Why?
|
Organoids | 2 | 2022 | 94 | 0.360 |
Why?
|
Muscle Development | 3 | 2020 | 49 | 0.360 |
Why?
|
Endothelial Cells | 4 | 2014 | 189 | 0.330 |
Why?
|
Humans | 23 | 2022 | 32114 | 0.310 |
Why?
|
Mice, Nude | 5 | 2020 | 291 | 0.310 |
Why?
|
Cell Movement | 1 | 2008 | 169 | 0.300 |
Why?
|
Cadherins | 1 | 2007 | 26 | 0.300 |
Why?
|
Protein-Serine-Threonine Kinases | 1 | 2007 | 50 | 0.290 |
Why?
|
Apoptosis | 4 | 2008 | 360 | 0.290 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2004 | 82 | 0.290 |
Why?
|
Fibrosis | 2 | 2017 | 120 | 0.280 |
Why?
|
Tissue Scaffolds | 4 | 2014 | 415 | 0.270 |
Why?
|
DNA Damage | 2 | 2003 | 99 | 0.270 |
Why?
|
Cell Proliferation | 4 | 2017 | 604 | 0.260 |
Why?
|
Cell Survival | 4 | 2020 | 285 | 0.260 |
Why?
|
Receptor, IGF Type 1 | 1 | 2005 | 7 | 0.250 |
Why?
|
Immediate-Early Proteins | 1 | 2005 | 9 | 0.250 |
Why?
|
src-Family Kinases | 1 | 2005 | 16 | 0.250 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2005 | 37 | 0.250 |
Why?
|
Female | 9 | 2022 | 20015 | 0.250 |
Why?
|
Breast Neoplasms | 3 | 2009 | 765 | 0.250 |
Why?
|
MAP Kinase Signaling System | 1 | 2005 | 61 | 0.240 |
Why?
|
DNA-Binding Proteins | 1 | 2005 | 147 | 0.230 |
Why?
|
Repressor Proteins | 1 | 2003 | 50 | 0.220 |
Why?
|
Blood Vessel Prosthesis | 2 | 2014 | 83 | 0.220 |
Why?
|
Gene Expression Regulation | 2 | 2005 | 495 | 0.220 |
Why?
|
Fiber Optic Technology | 2 | 2013 | 15 | 0.210 |
Why?
|
Hyaluronic Acid | 2 | 2020 | 52 | 0.210 |
Why?
|
Pituitary Gland | 1 | 2022 | 9 | 0.210 |
Why?
|
Pituitary-Adrenal System | 1 | 2022 | 21 | 0.210 |
Why?
|
Heparin | 2 | 2020 | 73 | 0.210 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2022 | 31 | 0.210 |
Why?
|
Male | 8 | 2022 | 19217 | 0.200 |
Why?
|
Necrosis | 1 | 2022 | 53 | 0.200 |
Why?
|
Neoplasms | 4 | 2020 | 728 | 0.190 |
Why?
|
Cell Line, Tumor | 3 | 2008 | 726 | 0.180 |
Why?
|
Radiation, Ionizing | 3 | 2005 | 23 | 0.180 |
Why?
|
Isometric Contraction | 2 | 2017 | 23 | 0.180 |
Why?
|
Fluorescent Dyes | 2 | 2018 | 48 | 0.180 |
Why?
|
Free Radical Scavengers | 1 | 2020 | 14 | 0.180 |
Why?
|
Green Fluorescent Proteins | 2 | 2017 | 71 | 0.170 |
Why?
|
History, 21st Century | 1 | 2020 | 59 | 0.170 |
Why?
|
History, 20th Century | 1 | 2020 | 71 | 0.170 |
Why?
|
DNA Repair | 1 | 2020 | 64 | 0.170 |
Why?
|
Adult Stem Cells | 1 | 2020 | 25 | 0.170 |
Why?
|
Stem Cell Transplantation | 2 | 2020 | 209 | 0.170 |
Why?
|
Sus scrofa | 3 | 2017 | 46 | 0.170 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2020 | 105 | 0.170 |
Why?
|
Promoter Regions, Genetic | 3 | 2005 | 208 | 0.160 |
Why?
|
Hydrogels | 1 | 2020 | 121 | 0.160 |
Why?
|
Body Weight | 2 | 2017 | 310 | 0.160 |
Why?
|
Analysis of Variance | 1 | 2020 | 464 | 0.160 |
Why?
|
Microscopy, Fluorescence | 3 | 2014 | 88 | 0.160 |
Why?
|
Cell Line | 4 | 2018 | 435 | 0.160 |
Why?
|
Cell Cycle | 2 | 2016 | 77 | 0.150 |
Why?
|
Clusterin | 4 | 2006 | 6 | 0.150 |
Why?
|
Neoplasm Invasiveness | 2 | 2009 | 190 | 0.150 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 91 | 0.150 |
Why?
|
Organ Size | 1 | 2017 | 218 | 0.140 |
Why?
|
Myoblasts, Skeletal | 1 | 2016 | 19 | 0.140 |
Why?
|
Kidney | 1 | 2020 | 518 | 0.140 |
Why?
|
RNA, Small Interfering | 2 | 2008 | 114 | 0.140 |
Why?
|
Pressure | 2 | 2017 | 51 | 0.130 |
Why?
|
Urinary Incontinence, Stress | 1 | 2016 | 65 | 0.130 |
Why?
|
NF-kappa B | 2 | 2008 | 81 | 0.130 |
Why?
|
Urethra | 1 | 2017 | 102 | 0.130 |
Why?
|
Extracellular Matrix | 1 | 2017 | 245 | 0.130 |
Why?
|
Mitochondrial Membranes | 1 | 2014 | 21 | 0.120 |
Why?
|
Endopeptidases | 1 | 2014 | 26 | 0.120 |
Why?
|
Cross-Linking Reagents | 1 | 2014 | 16 | 0.120 |
Why?
|
Mitochondrial Proteins | 1 | 2014 | 66 | 0.110 |
Why?
|
Oxygen Consumption | 1 | 2014 | 154 | 0.110 |
Why?
|
Age Factors | 2 | 2014 | 1189 | 0.110 |
Why?
|
Bioprosthesis | 1 | 2014 | 58 | 0.110 |
Why?
|
Energy Metabolism | 1 | 2014 | 147 | 0.110 |
Why?
|
Mice, Transgenic | 2 | 2016 | 264 | 0.110 |
Why?
|
Endothelium, Corneal | 1 | 2013 | 22 | 0.110 |
Why?
|
Implants, Experimental | 1 | 2012 | 12 | 0.110 |
Why?
|
Mitochondria | 1 | 2014 | 187 | 0.110 |
Why?
|
Radiation | 1 | 2012 | 1 | 0.100 |
Why?
|
Coculture Techniques | 1 | 2012 | 81 | 0.100 |
Why?
|
Mass Media | 1 | 2012 | 12 | 0.100 |
Why?
|
Prosthesis Implantation | 1 | 2012 | 40 | 0.100 |
Why?
|
Muscular Diseases | 1 | 2012 | 22 | 0.100 |
Why?
|
Endothelium, Vascular | 1 | 2013 | 156 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 112 | 0.100 |
Why?
|
Desmin | 1 | 2011 | 12 | 0.100 |
Why?
|
Myositis | 1 | 2011 | 10 | 0.100 |
Why?
|
Carotid Arteries | 1 | 2012 | 99 | 0.100 |
Why?
|
Mutation | 1 | 2014 | 489 | 0.100 |
Why?
|
Research | 1 | 2012 | 74 | 0.100 |
Why?
|
Edema | 1 | 2011 | 28 | 0.100 |
Why?
|
Ligation | 1 | 2011 | 56 | 0.100 |
Why?
|
Cells, Cultured | 4 | 2017 | 834 | 0.100 |
Why?
|
United States | 1 | 2020 | 3976 | 0.090 |
Why?
|
Wound Healing | 1 | 2012 | 185 | 0.090 |
Why?
|
Muscle Strength | 1 | 2011 | 161 | 0.090 |
Why?
|
Quality of Life | 1 | 2016 | 946 | 0.090 |
Why?
|
Phospholipase D | 1 | 2009 | 4 | 0.080 |
Why?
|
Isoenzymes | 1 | 2009 | 61 | 0.080 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2008 | 6 | 0.080 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2008 | 29 | 0.080 |
Why?
|
Transplantation, Heterologous | 1 | 2008 | 122 | 0.080 |
Why?
|
Enzyme Inhibitors | 1 | 2009 | 166 | 0.080 |
Why?
|
Up-Regulation | 1 | 2008 | 189 | 0.080 |
Why?
|
RNA, Untranslated | 1 | 2007 | 10 | 0.070 |
Why?
|
Mammary Glands, Human | 1 | 2007 | 15 | 0.070 |
Why?
|
Signal Transduction | 2 | 2008 | 682 | 0.070 |
Why?
|
RNA Interference | 1 | 2007 | 76 | 0.070 |
Why?
|
Cell Physiological Phenomena | 1 | 2006 | 3 | 0.070 |
Why?
|
Down-Regulation | 1 | 2007 | 142 | 0.070 |
Why?
|
Feedback, Physiological | 1 | 2006 | 10 | 0.070 |
Why?
|
Epithelial Cells | 1 | 2007 | 141 | 0.070 |
Why?
|
Primates | 2 | 2017 | 108 | 0.070 |
Why?
|
Transforming Growth Factor beta | 1 | 2006 | 64 | 0.070 |
Why?
|
Early Growth Response Protein 1 | 1 | 2005 | 4 | 0.060 |
Why?
|
Bystander Effect | 1 | 2004 | 6 | 0.060 |
Why?
|
Genomic Instability | 1 | 2004 | 6 | 0.060 |
Why?
|
PAX7 Transcription Factor | 2 | 2016 | 8 | 0.060 |
Why?
|
Enzyme Activation | 1 | 2005 | 135 | 0.060 |
Why?
|
Radiation Tolerance | 1 | 2004 | 24 | 0.060 |
Why?
|
Lung Neoplasms | 1 | 2008 | 414 | 0.060 |
Why?
|
Oncogene Proteins, Viral | 1 | 2003 | 3 | 0.060 |
Why?
|
Complement Inactivator Proteins | 1 | 2003 | 3 | 0.060 |
Why?
|
Cyclins | 1 | 2003 | 6 | 0.060 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2003 | 9 | 0.060 |
Why?
|
Cytoplasm | 1 | 2003 | 29 | 0.060 |
Why?
|
Gamma Rays | 1 | 2003 | 25 | 0.060 |
Why?
|
Colonic Neoplasms | 1 | 2003 | 71 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2003 | 137 | 0.050 |
Why?
|
Optics and Photonics | 2 | 2012 | 7 | 0.050 |
Why?
|
Neoplasm Proteins | 1 | 2003 | 148 | 0.050 |
Why?
|
Microcirculation | 2 | 2012 | 65 | 0.050 |
Why?
|
Bioreactors | 2 | 2012 | 60 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2006 | 608 | 0.050 |
Why?
|
Equipment Design | 2 | 2012 | 171 | 0.050 |
Why?
|
RNA, Messenger | 1 | 2003 | 508 | 0.050 |
Why?
|
Cisplatin | 1 | 2020 | 76 | 0.050 |
Why?
|
Nerve Regeneration | 1 | 2020 | 48 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2020 | 104 | 0.040 |
Why?
|
Myogenic Regulatory Factor 5 | 1 | 2018 | 7 | 0.040 |
Why?
|
Transforming Growth Factor alpha | 1 | 2018 | 4 | 0.040 |
Why?
|
Wnt Proteins | 1 | 2018 | 18 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2003 | 471 | 0.040 |
Why?
|
Cell Count | 1 | 2017 | 47 | 0.040 |
Why?
|
Organ Specificity | 1 | 2017 | 81 | 0.040 |
Why?
|
Gluconates | 1 | 2016 | 4 | 0.040 |
Why?
|
Ouabain | 1 | 2016 | 6 | 0.040 |
Why?
|
Potassium | 1 | 2016 | 40 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2016 | 78 | 0.030 |
Why?
|
Membrane Potentials | 1 | 2016 | 81 | 0.030 |
Why?
|
Social Behavior | 1 | 2017 | 65 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2017 | 185 | 0.030 |
Why?
|
Blotting, Western | 1 | 2016 | 289 | 0.030 |
Why?
|
DNA | 1 | 2017 | 226 | 0.030 |
Why?
|
Collagen | 1 | 2017 | 225 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2016 | 538 | 0.030 |
Why?
|
Macaca fascicularis | 1 | 2016 | 434 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 633 | 0.030 |
Why?
|
Mice, Mutant Strains | 1 | 2014 | 52 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 767 | 0.030 |
Why?
|
Adult | 2 | 2020 | 9380 | 0.030 |
Why?
|
Collagen Type IV | 1 | 2013 | 8 | 0.030 |
Why?
|
Collagenases | 1 | 2013 | 9 | 0.030 |
Why?
|
Biomedical Engineering | 1 | 2013 | 26 | 0.030 |
Why?
|
Fibronectins | 1 | 2013 | 36 | 0.030 |
Why?
|
Culture Media | 1 | 2013 | 47 | 0.030 |
Why?
|
Polyesters | 1 | 2013 | 76 | 0.030 |
Why?
|
Young Adult | 1 | 2020 | 2665 | 0.030 |
Why?
|
Photons | 1 | 2012 | 7 | 0.030 |
Why?
|
Silicon Dioxide | 1 | 2012 | 9 | 0.030 |
Why?
|
Electrons | 1 | 2012 | 12 | 0.030 |
Why?
|
Cell Shape | 1 | 2012 | 28 | 0.030 |
Why?
|
Light | 1 | 2012 | 24 | 0.030 |
Why?
|
Microspheres | 1 | 2012 | 44 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2012 | 65 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2012 | 60 | 0.030 |
Why?
|
Swine | 1 | 2012 | 215 | 0.020 |
Why?
|
Odds Ratio | 1 | 2013 | 472 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2012 | 266 | 0.020 |
Why?
|
Time Factors | 1 | 2016 | 2151 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2012 | 173 | 0.020 |
Why?
|
Models, Statistical | 1 | 2012 | 175 | 0.020 |
Why?
|
Sex Factors | 1 | 2013 | 667 | 0.020 |
Why?
|
Urinary Bladder | 1 | 2012 | 182 | 0.020 |
Why?
|
Skin | 1 | 2012 | 211 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2017 | 3306 | 0.020 |
Why?
|
Drug Design | 1 | 2009 | 43 | 0.020 |
Why?
|
Naphthoquinones | 1 | 2006 | 2 | 0.020 |
Why?
|
DNA Mismatch Repair | 1 | 2006 | 4 | 0.020 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2006 | 15 | 0.020 |
Why?
|
Cell Death | 1 | 2006 | 77 | 0.020 |
Why?
|
Ligands | 1 | 2006 | 81 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2006 | 220 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2004 | 57 | 0.020 |
Why?
|
Models, Biological | 1 | 2006 | 392 | 0.010 |
Why?
|
Proteins | 1 | 2004 | 144 | 0.010 |
Why?
|
Aged | 1 | 2013 | 10314 | 0.010 |
Why?
|
Middle Aged | 1 | 2013 | 11839 | 0.010 |
Why?
|